
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Will psychiatrists be better able to play a role in improving health outcomes in obese patients? Weigh in here.
With the American Medical Association
Related links:




